INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
5.33
-0.95 (-15.13%)
At close: Jun 27, 2025, 4:00 PM
2.030
-3.300 (-61.91%)
Pre-market: Jun 30, 2025, 8:21 AM EDT
INmune Bio Revenue
INmune Bio had revenue of $50.00K in the quarter ending March 31, 2025, with 257.14% growth. This brings the company's revenue in the last twelve months to $50.00K, down -61.83% year-over-year. In the year 2024, INmune Bio had annual revenue of $14.00K, down -90.97%.
Revenue (ttm)
$50.00K
Revenue Growth
-61.83%
P/S Ratio
2,474.23
Revenue / Employee
$2,273
Employees
22
Market Cap
123.71M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14.00K | -141.00K | -90.97% |
Dec 31, 2023 | 155.00K | -219.00K | -58.56% |
Dec 31, 2022 | 374.00K | 193.00K | 106.63% |
Dec 31, 2021 | 181.00K | 170.00K | 1,545.45% |
Dec 31, 2020 | 11.00K | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
INMB News
- 47 minutes ago - INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study - Reuters
- 53 minutes ago - INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease - GlobeNewsWire
- 2 days ago - INmune Bio: Finding Pay Dirt In Alzheimer's? - Seeking Alpha
- 2 days ago - INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 2 days ago - INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes - Benzinga
- 3 days ago - INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th - GlobeNewsWire
- 13 days ago - INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity - Seeking Alpha
- 6 weeks ago - INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity - Seeking Alpha